Navigation Links
Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
Date:8/11/2008

- Conference Call Today at 4:30 p.m. Eastern Time -

SAN FRANCISCO, Aug. 11 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today reported on its corporate progress and financial results for the quarter ended June 30, 2008.

"Based on the significant findings of the Dimebon 12-month pivotal trial in Alzheimer's disease recently published in The Lancet, as well as the promising results from our Phase 2 study in Huntington's disease announced last month, we believe Dimebon is among the most promising drug candidates being investigated today to treat patients with debilitating, and ultimately fatal, neurodegenerative diseases," said David Hung, M.D., president and chief executive officer of Medivation. "We are making excellent progress opening U.S. sites and enrolling patients in our confirmatory Phase 3 trial of Dimebon in Alzheimer's disease, and remain on target to complete the study in time to file for U.S. marketing approval for Alzheimer's disease in 2010. In addition, we continue to increase the dose and enroll patients in our ongoing Phase 1-2 study of MDV3100 for castration-resistant prostate cancer. We remain on track for completing that study later this year, after which we intend to seek FDA approval to enter Phase 3 in 2009."

Second Quarter Highlights and Recent Accomplishments

Alzheimer's Disease

-- Initiated dosing of patients in a second pivotal Phase 3 trial of the

investigational drug Dimebon in patients with mild-to-moderate

Alzheimer's disease. This international, double-blind,

placebo-controlled safety and efficacy study of oral Dimebon, known as

the CONNECTION study, will enroll approximately 525 patients at 60 to

80 cl
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
2. Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
3. Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
4. Medivation Announces Senior Management Promotions
5. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients
6. Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 5
7. Medivation Announces Second Quarter 2008 Teleconference and Webcast on August 11, 2008
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Report Details Biosimilar drugs – ... Do you want to find sales potentials of ... for those biological drugs from 2014, helping you ... data, R&D trends, opportunities and selling prospects. In ... 2024 at overall world market, therapeutic class, molecule ...
(Date:9/30/2014)... September 30, 2014 Proove Biosciences ... is excited to announce a new genetic test built ... Proove Pain Perception Test will provide physicians with ... why pain tolerance levels are stratified between individuals. With ... whether a person has a genetic predisposition that will ...
(Date:9/30/2014)... BUDAPEST, Hungary , September 30, 2014 /PRNewswire/ ... libraries and intuitive browsing of chemistry in documents ... providing chemistry software solutions and consulting services for ... extract chemical information and generate Markush structures from ... securing an organizations intellectual property, however generating and ...
(Date:9/30/2014)... and ROCKVILLE, Md., Sept. 30, 2014 ... focusing on commercializing market-relevant biohealth innovations and increasing access ... , announced today that venture capitalist, Tania Fernandez ... strategic advisor. Dr. Fernandez will be a member of ... which will provide up to $50 million in seed ...
Breaking Biology Technology:Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2
... 11, 2011 Novavax, Inc. (Nasdaq: NVAX ... by the Tech Council of Maryland (TCM), the largest ... communities of Maryland.  Novavax was recognized as the firm ... community and for its presence and leadership in Maryland. ...
... May 11, 2011 Verenium Corporation (Nasdaq: ... the development and commercialization of high-performance enzymes, ... will present at two upcoming conferences. Mr. ... Solutions Conference as part of the "Biofuels" panel discussion ...
... Ill., May 11, 2011 Naurex Inc., a clinical-stage ... psychiatry and neurology, today announced the completion of an ... Partners and Latterell Venture Partners.  Druid BioVentures, Genesys Capital, ... in the round.  Naurex will use the proceeds from ...
Cached Biology Technology:Novavax Named Biotechnology Firm of the Year by Tech Council of Maryland 2Verenium to Present at Upcoming Conferences 2Verenium to Present at Upcoming Conferences 3Naurex Completes $18 Million Series A Financing 2Naurex Completes $18 Million Series A Financing 3Naurex Completes $18 Million Series A Financing 4Naurex Completes $18 Million Series A Financing 5Naurex Completes $18 Million Series A Financing 6Naurex Completes $18 Million Series A Financing 7
(Date:9/30/2014)... your doctor to know what goes wrong with your muscles ... to know what "normal" actually is. That,s where a new ... FASEB Journal comes in. In the ... set of molecules that can help scientists "see" which genes ... more, they found never-before-detected gene activity and that men have ...
(Date:9/30/2014)... ARLINGTON HEIGHTS, Ill. (September 30, 2014) People who ... they can do to control their asthma besides properly ... to a new article in the Annals of ... the American College of Allergy, Asthma and Immunology (ACAAI), ... by examining their lifestyle. The woman described in the ...
(Date:9/29/2014)... DC Monday, September 29: Between 1970 and ... fish around the globe dropped 52 percent, says ... World Wildlife Fund (WWF). This biodiversity loss occurs ... resource use of high-income countries. , In addition ... report,s data point to other warning signs about ...
Breaking Biology News(10 mins):Scientists identify which genes are active in muscles of men and women 2Asthma symptoms kicking up? Check your exposure to air pollution 2Half of global wildlife lost, says new WWF report 2
... part of the Genome Canada Large-Scale Applied Research Project ... to 16 projects across the country, the researchers in ... with the aim of identifying genes or proteins for ... target cancers and other diseases. The first project, ...
... - New research from the University of Calgary,s Faculty ... diagnosis using an iPhone application with the same accuracy ... technology can be particularly useful in rural medical settings. ... neurologists, regardless of where the physicians and patients are ...
... has revealed how infection by a parasitic fungus dramatically changes ... leonardi ), causing them to become zombie-like and to die ... fungus. The multinational research team studied ants living high up ... research will be published in the BioMed Central open-access journal ...
Cached Biology News:OGI genomics researchers awarded $23 million 2OGI genomics researchers awarded $23 million 3iPhone can diagnose stroke: study 2Zombie ants have fungus on the brain, new research reveals 2
Request Info...
Agarose-LE, 500 g. Suitable for soft agarose cloning. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1200 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Request Info...
Request Info...
Biology Products: